---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-105905"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-09-08T20:06:07+00:00"
generated_at: "2026-09-08T20:07:26.159835+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo completes $50M asset sale to Eli Lilly, files July Chapter 11 operating report

## Summary
- Completed $50M asset sale to Eli Lilly on 9/4/26; includes STAC-BBB capsid, zinc finger, modular integrase platforms, and prion program ST-506.
- July 2026 MOR: cash $16.9M, assets $155.1M, liabilities $97.1M; pre-petition unsecured debt $78.1M, post-petition debt $19.0M.
- July operating report: net loss $11.2M for month, cumulative loss $14.9M; G&A $3.8M, reorganization items $4.2M.
- Chapter 11 filed 6/23/26; court approved sale 8/20/26; stock delisted from Nasdaq, trades OTC as SGMOQ.

## SEC filing metadata
- accession: 0001104659-26-105905
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-09-08T20:06:07+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.03, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/0001104659-26-105905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/tm2624942d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-105905
- JSON: https://secwatch.observer/filing/0001104659-26-105905.json
- Plain text: https://secwatch.observer/filing/0001104659-26-105905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.